Bio‑Sourcing SA (‘Bio-Sourcing’) and The Tiny Cargo Company (‘Tiny Cargo’) today announce a strategic collaboration to co‑develop oral therapies based on monoclonal antibodies (mAbs) that leverage goat‑milk extracellular vesicles (EVs), including exosomes. This partnership unites Bio‑Sourcing’s unique ability to produce high‑quantity, low‑cost monoclonal antibodies and goat‑milk EVs with Tiny Cargo’s world-first, cGMP-ready industrial platform for purifying and loading milk-derived exosomes with complex therapeutic payloads. Together these enable the enrichment of these antibodies within exosomes to enhance their concentration, potency and suitability for oral delivery.

Oral delivery of mAbs promises clear benefits for patients and health systems: no needles and fewer hospital visits, with a path to stable, shelf‑ready formulations. Milk‑derived exosomes are naturally designed to survive the gastrointestinal tract and deliver antibodies to the bloodstream, making them an especially promising carrier.

Bio‑Sourcing’s platform expresses monoclonal antibodies in the milk of a particular breed of goats at an industrial scale, enabling purification of the antibody while also producing milk EVs. The platform’s cost and scalability advantages over conventional bioreactors open the door to broader access and sustainable manufacturing.

Tiny Cargo has developed the world’s first cGMP-ready industrial manufacturing capability for highly purified milk-derived exosomes, supported by proprietary purification and loading processes designed to isolate exosomes from milk and incorporate complex therapeutic payloads. The platform is designed for pharmaceutical-grade production and supports applications across therapeutics, nutraceuticals and advanced skincare.

With this collaboration, both companies will associate Bio‑Sourcing‑derived mAbs with goat‑milk EVs and evaluate therapeutic applications via the oral route, with the shared objective of building a new class of patient‑friendly, stable biologics. To date, there are no approved oral mAbs, underscoring the innovation potential of this alliance.

“With Tiny Cargo, we’re pairing two outstanding product platforms — Bio‑Sourcing’s high‑yield, sustainable goat‑milk manufacturing of monoclonal antibodies and milk EVs with Tiny Cargo’s industrial‑scale milk exosome isolation and loading — to unlock true oral delivery for biologics. We are eager to create a successful and long‑term strategic alliance with mutual benefits; one that broadens Bio‑Sourcing’s access to other American collaborations, while offering Tiny Cargo a strong foothold in Europe. Together, we will make patient‑friendly biologics more accessible worldwide,” said Bertrand Mérot, founder and CEO, Bio‑Sourcing SA.

“Milk-derived exosomes are among the most resilient delivery systems in nature,” said Alan Gourdie, CEO of The Tiny Cargo Company. “The ability to source both the antibody and the delivery vehicle from the same biological starting point is a rare and powerful advantage. For the hundreds of millions of patients currently reliant on injectable mAbs, transitioning to an oral format would fundamentally transform how biologics are prescribed, distributed and accessed globally.”